These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 12577466)

  • 21. AT1-receptor antagonism in hypertension: what has been learned with irbesartan?
    Waeber B; Burnier M
    Expert Rev Cardiovasc Ther; 2003 May; 1(1):23-33. PubMed ID: 15030294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet activation in hypertension associated with hypercholesterolemia: effects of irbesartan.
    Alexandru N; Popov D; Dragan E; Andrei E; Georgescu A
    J Thromb Haemost; 2011 Jan; 9(1):173-84. PubMed ID: 20961397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
    Man in't Veld AJ
    J Hypertens Suppl; 1997 Dec; 15(7):S27-33. PubMed ID: 9532518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK954, in patients with essential hypertension].
    Hagino T; Abe K; Tsunoda K; Yoshinaga K
    Nihon Jinzo Gakkai Shi; 1992 Feb; 34(2):133-40. PubMed ID: 1588765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats.
    Cao Z; Bonnet F; Davis B; Allen TJ; Cooper ME
    Clin Sci (Lond); 2001 Jun; 100(6):591-9. PubMed ID: 11352773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan.
    Bunt T
    Clin Ther; 1999 Mar; 21(3):611-2. PubMed ID: 10321426
    [No Abstract]   [Full Text] [Related]  

  • 28. [Drug clinics. Drug of the month. Irbesartan (Aprovel)].
    Kulbertus H
    Rev Med Liege; 1999 Feb; 54(2):125-7. PubMed ID: 10221067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Irbesartan--a new AT1-receptor antagonist (AT1-blocker). Angiotensin-II-receptor antagonists: perspectives of a new therapeutic principle, Wiesbaden, 6 April 1997].
    Dtsch Med Wochenschr; 1997 Sep; 122(37 Suppl):1-4. PubMed ID: 9330579
    [No Abstract]   [Full Text] [Related]  

  • 30. Cardiac autonomic tone during trandolapril-irbesartan low-dose combined therapy in hypertension: a pilot project.
    Franchi F; Lazzeri C; Foschi M; Tosti-Guerra C; Barletta G
    J Hum Hypertens; 2002 Aug; 16(8):597-604. PubMed ID: 12149667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New angiotensin-II blocker.
    Lilley LL; Guanci R
    Am J Nurs; 1996 Mar; 96(3):20. PubMed ID: 8607540
    [No Abstract]   [Full Text] [Related]  

  • 32. Irbesartan for hypertension.
    Med Lett Drugs Ther; 1998 Jan; 40(1019):18-9. PubMed ID: 9465857
    [No Abstract]   [Full Text] [Related]  

  • 33. Involvement of the AT(2)-receptor in angiotensin II-induced facilitation of sympathetic neurotransmission.
    Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
    J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):181-7. PubMed ID: 12563569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fimasartan.
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):249-52. PubMed ID: 21740078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin receptor antagonists.
    Wong W; Howes L
    Aust Fam Physician; 2000 Jul; 29(7):653-5, 658. PubMed ID: 10914449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Irbesartan in the treatment of arterial hypertension].
    Widimský J; Zizka J; Haas T
    Vnitr Lek; 2000 Jun; 46(6):337-40. PubMed ID: 15645839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Angiotensin receptor antagonists. A new class of antihypertensive agents].
    Mann J
    Dtsch Med Wochenschr; 1996 Apr; 121(17):568-71. PubMed ID: 8620827
    [No Abstract]   [Full Text] [Related]  

  • 38. The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man.
    Belz GG; Breithaupt-Grögler K; Butzer R; Fuchs W; Hausdorf C; Mang C
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):336-41. PubMed ID: 11967820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data].
    Paoletti V; Di Veroli C; Pugliese M; Cammarella I; Cavina G; Turchetti P; Mammarella A
    Clin Ter; 2002; 153(1):61-4. PubMed ID: 11963637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
    Nussberger J; Aubert JF; Bouzourene K; Pellegrin M; Hayoz D; Mazzolai L
    Hypertension; 2008 May; 51(5):1306-11. PubMed ID: 18391092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.